It was initially developed because improper activation of EGFR signaling appears frequently in lung cancer, thus, ASCO guidelines recommended GEF for the treatment of advanced NSCLC in second- or third-line settings (Azzoli et al., 2010). Here, EGFR is linked to non-small cell lung carcinoma.